fouremm......you may be right, although I'm sure many on this board are feeling a bit more hopeful than they were before the AGM.  Anyway, time will tell.

Clearly RVX management want to get BOM2 done, even if that means selling some Zenith assets at less than favorable prices.  However, given that the outcome of a BOM2 trial is supposedly pretty much a slam dunk (p= 0.002) after seeing the results of BOM and will therefore easily meet FDA requirements to proceed with commercialization, why is it so hard to get any player with deep pockets to pony up $140M to get the trial done?  Furthermore, if Zenith is such a winner financially when only looking at the one indication (NUT Carcinoma), why are there not competing bids out there to pony up for something that is supposedly a no-brainer financially?  But then who knows, maybe I'm just naive.

For the past few years timelines have continually been pushed back, and back, and back some more.  The future depends on getting ahold of the funds to do BOM2 and then actually being able to do the trial itself.  2027 is 3 years out and that may get pushed back as well.  We'll see.

For me to get out even I need about $C0.80/share.  If they can actually secure the funds to proceed with BOM2 then I don't think that SP target will be too unrealistic.  The question then will be, what do I do now??